Abstract. IGFs were extracted from Cohn fraction IV of human plasma using ultrafiltration of acidified paste as the initial step. Further 
peptides (A2 and B3) appear to be two-chain forms of IGF-II and IGF-I, respectively, as shown by structural analysis and polyacrylamide gel electrophoresis. One peptide (Al) appears to be a new variant of an IGF-II derivative with a substitution of Ser by Cys in position 29 . Further analysis involved reactivity in radioreceptor assays for IGF-I and IGF-II. N2, Al and A2 are IGF-II\x=req-\ like, whereas B2 and B3 are IGF-I-like, though there are important differences with the main IGFs. Similar results were obtained in IGF-I and IGF-II C-peptide radioimmunoassays. The physiological significance of these peptides is unknown. They offer interesting perspectives for structure-function analysis.
The heterogeneity of insulin-like growth factors (IGF, somatomedins) in extracts of human plasma or serum has been noted since the earliest attempts to isolate and characterize them (1) (2) (3) . While side fractions with somatomedin and/or insulin-like ac¬ tivity were observed by many authors (4) (5) (6) (7) (8) (9) (10) (11) , the focus has been on the two main acid extractablesomatomedins: IGF-I (12, 13) and IGF-II (14) .
IGFs are synthesized in a pre-pro form, thus re¬ quiring processing before the mature stage is reached (15, 16) . In addition, variation, probably allelic, has been demonstrated by us by the isolation of a cDNA encoding an IGF-II variant, obtained from the same donor liver containing the cDNA encoding IGF-II (16) .
The characterization of minor IGF fractions ob¬ tained from human plasma or serum is important, since they may represent either products of allelic variations or compounds at a different stage of pro¬ cessing of the expression products of the IGF genes. The variant pro-form of IGF-II described by Zumstein et al. (17) may represent such an in¬ completely processed variant. Processing beyond the stage of the main plasma IGFs seems also to occur, as exemplified by the the truncated IGF-I described by Sara and coworkers (18, 19) . Both the acidic IGF-I-like peptide fraction studied by He- rington & Kuffer (20) , and the peptides isolated by Blum et al. (21) may be other examples of such metabolites. Their physiological significance is at present unknown.
In a previous report we described the partial pu¬ rification of different IGF activity-containing frac¬ tions from human and porcine plasma and from human Cohn fraction IV (22) . The present paper describes the isolation of IGF-like peptides from human Cohn fraction IV, their structural charac¬ teristics, and their behaviour in different radioreceptor and radioimmunological assay systems.
Materials and Methods
Cohn fraction IV (Cohn IV) from human plasma (23) was kindly made available by Dr. H. G. J. Brummelhuis (26) with the mod¬ ifications described by Takano (27) .
Assay methods
A radioreceptor assay (RRA) was used for routine mea¬ surement of the somatomedin activity using human pla¬ cental membranes (28) with 125I-labelled IGF-I, IGF-II or insulin as tracer.
To measure IGF-II-like activity more specifically a mouse liver membrane RRA was applied using l2T-IGF-II as tracer (29) . Recently an improved RRA using bovine placental cell membranes has also been applied (30) .
Immunoreactive IGF-I was determined by RIA in each plasma sample by a non-equilibrium technique (31) with slight modifications (29 
Expression of assay results
In early experiments (Fig. 1 (10) . The gradients are depicted in Fig. 4 All purified peptides were subjected to amino acid analysis as the basis for expressing the amounts of pep¬ tide.
SDS polyacrylamide gel electrophoresis
The purified peptides were subjected to SDS-PAGE (33) with minor modifications for separating the 125I-Iodinated analogues. They were run on a 10% acrylamide gel with bisacrylamide: acrylamide 10:1 in 0.1 mol/l H3P04/TRIS buffer, pH 5, 0.1 % SDS, and 8 mol/l urea in a vertical slab gel apparatus (Biorad) at 20 mA/gel for 30 min followed by [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] (34) . Details have been reported (35) . Each spec-trum was individually calibrated on the basis of the peaks corresponding to H+ and NO+, and the calibration con¬ stants were checked against porcine insulin. The samples, 0.05-0.2 nmol, were dissolved in 5 ul of 0.1% TFA solu¬ tion adsorbed on the nitrocellulose-covered support by the spin-technique (36) Protein-containing peaks were collected, centrifuged, lyo¬ philized, re-dissolved in 0.07 ml of formic acid, and 0.03 ml was used for amino acid sequence analysis (37 Fig. 1 , where the pattern obtained in a simple acid extract of Cohn IV is compared with a preparation obtained after acid filtraction. After IEF, activity was estimated by IGF-I RRA, measuring both IGF-I and IGF-II, and also by the IGF-I RIA (Fig.  2) . The overall profile shown in Fig. 1 necessary (Fig. 3) . The other peptides were puri¬ fied by application of system I (utilizing the pre¬ parative column), system II (on the analytical column) followed by desalting on the analytical column using system I (Fig. 4) . The acid fractions were considered pure only after a third and fourth run using system II and I, respectively ( Fig. 5) . Only peak fractions were utilized for structural analysis (see below). The yields after HPLC are shown in Table 2 . Identification and behaviour in different assay systems All peptide fractions were tested in different assay systems. The present evaluations are preliminary and will be followed-up by more detailed studies using the labelled peptides. The results will be re¬ ported subsequently. However, the data allow for an overall impression of relative activities of the different peptides.
As an example, the displacement curves ob¬ tained in the RIA for IGF-I are shown in Fig. 8 . They immediately allow distinction between the peptides which are IGF-I like and those which are IGF-II-like. All other tests were done similarly with full length displacement curves. Results are sum¬ marized in Table 6 .
Since all results assigned the identity of Bl to IGF-I and of Nl to IGF-II, the behaviour of the other peptide fractions were compared with these two marker peptides. The most basic peptide (B2, pi 9.4) which, neither by molecular weight nor by sequence analysis showed differences from IGF-I, was somewhat less active but still similar to IGF-I by its potency in the RIA and RRA for IGF-I and similar in the insulin-RRA. While its cross-reactivity in the CP-II RIA was preserved, its competition with I25I-IGF-II in receptor preparations from human placenta and mouse liver was poor suggest¬ ing, diminished reactivity with the type II receptor.
The two-chain IGF-I-like peptide isolated with pi 7.8 (B3) was similar to the previous peptide with the exception of a low reactivity in the IGF-I radioreceptor assay.
N2, indistinguishable in its major component, The acid peptides, Al and A2, structurally re¬ lated to IGF-II, showed rather low reactivity in the RRAs. However, Al showed a good reactivity with the CP-II directed antibody in the CP-II-RIA, whereas A2, the two-chain IGF-II-like peptide, showed low reactivity. As expected all peptides measured in the insulin receptor assay showed a low reactivity.
Discussion
The isolation of IGF-I and IGF-II has allowed the development of sensitive assays for the study of their levels in physiological and pathological con¬ ditions and has stimulated studies on their in vitro and in vivo effects. The elucidation of their pri- Tables 2 and 3 . Apparent sizes are not indicated in view of the known underestimation of IGFs in this system (43) .
mary structure has furthered the insight into their structural relationship with other insulin-like sub¬ stances and has been the basis for the isolation of cDNAs encoding them (38) . The presence in plasma and in Cohn fraction IV of other fractions with IGF-like activity, as mea¬ sured by bioassay or RRA, has been recognized (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 39 sulin-RRA are as described (12, 13, 41 Ala-Tyr. (15) Ala-Tyr. (32) Tyr-Arg. (24) IGF-II RRA "(human placenta)" "(mouse liver)" Insulin RRA**) "(human placenta)" 23 (18) 82 (5) Kuffer & Herrington (42) since this fraction behaves IGF-Ilike. On the other hand, the acid peptides may have been components of the acidic IGF-activity-containing fractions which have previously been dem¬ onstrated (1, 2, 6 (45, 46) .
